In BROSSARD, Quebec, on April 01, 2026, Diagnos Inc. (referred to as "DIAGNOS" or the "Corporation") has completed the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA). Specializing in early detection of eye-related health conditions through Artificial Intelligence (AI) methods, the company's stock is listed on TSX Venture as ADK, OTCQB as DGNOF, and FWB as 4D4A.